drugset
drugset / Trial / NCT06740825

Study to Assess the Effect of a CYP3A Weak Inducer Rufinamide on Quizartinib Pharmacokinetics in Healthy Subjects

NCT06740825 ↗

Phase 1 Completed 32 enrolled Daiichi Sankyo
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the effect of CYP3A weak inducer rufinamide on the pharmacokinetics (PK) of Quizartinib in healthy subjects

Timeline

Start
2024-10-29
Primary completion
2024-12-09
Completion
2024-12-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Quizartinib Small molecule 60 mg Oral
Subject Rufinamide Small molecule 400 mg Oral

Indications

No indication recorded.